Sarepta disclosed five insider transactions on March 13, 2026, including Director Mayo Stephen selling 7,239 shares on March 12. Executives also made multiple sell transactions on March 11 and March 9, involving different quantities and totaling tens of thousands of dollars. Sarepta is a biopharmaceutical company focused on RNA targeting and gene therapy.

K-LinePoet

2026-04-19 00:55:06

Abstract generation in progress

On March 13, 2026, Sarepta (SRPT) disclosed five insider trading transactions. Director Mayo Stephen sold 7,239 shares on March 12, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 13, 2026	Director	Mayo Stephen	March 12, 2026	Sell	7,239	17.02	$123.2k
March 13, 2026	Executive	Wong Ryan Ho-Yan	March 11, 2026	Sell	256	17.03	$4,359.68
March 13, 2026	Executive	Estepan Ian Michael	March 11, 2026	Sell	1,097	17.03	$18.7k
March 13, 2026	Executive	Rodino-Klapac Louise	March 11, 2026	Sell	948	17.03	$16.1k
March 13, 2026	Executive	Rothfuss Cristin	March 11, 2026	Sell	974	17.03	$16.6k
March 11, 2026	Executive	Estepan Ian Michael	March 9, 2026	Sell	1,619	16.95	$27.4k
March 11, 2026	Executive	Rothfuss Cristin	March 9, 2026	Sell	830	16.95	$14.1k
March 11, 2026	Executive	Wong Ryan Ho-Yan	March 9, 2026	Sell	275	16.95	$4,661.25
March 11, 2026	Executive	Rodino-Klapac Louise	March 9, 2026	Sell	1,399	16.95	$23.7k
March 3, 2026	Executive	Rothfuss Cristin	March 2, 2026	Sell	408	16.20	$6,610

【Company Profile】

Sarepta Therapeutics, Inc. was incorporated in Oregon on July 22, 1980. The company is a commercial-stage biopharmaceutical company focused on discovering and developing unique RNA-targeted therapies, gene therapies, and other genetic treatments for rare diseases. It has developed several approved drugs for Duchenne muscular dystrophy and is advancing candidate drugs for other neuromuscular and skeletal diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
223.78K Popularity
#
Gate13thAnniversaryLive
747.09K Popularity
#
AltcoinsRallyStrong
7.35M Popularity
#
AnthropicvsOpenAIHeatsUp
1.08M Popularity
#
KalshiFacesNevadaRegulatoryClash
473.38K Popularity

Sitemap

US stock insider trading | Sarepta disclosed 5 insider transactions on March 13

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin